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POPULAR SCIENCE SUMMARY 
Rheumatoid arthritis (RA) is a common autoimmune disease of the joints affecting 0,5-1% of 
the population. People affected by RA suffer from joint pain and have a reduced quality of life. 
Current treatment options can control RA progression, but do not cure the disease. Thus, RA 
is a problem for the persons affected by it but also from a socioeconomic standpoint. To 
develop improved treatment options, it is necessary to gain better understanding of the disease 
and its causes. Research suggests that susceptibility to arthritis is determined to a large extent 
by the natural variability in our genes. Understanding RA therefore means identifying and 
understanding the genes driving it.  
Unfortunately, identifying which genes are important for RA and understanding how they work 
is not a straightforward endeavour. There is a high variability in the human population which 
complicates data analysis and interpretation. Additionally, there is limited availability of 
relevant human samples, which makes it difficult to test new ideas and concepts in meaningful 
experiments. The immune system in mice largely mimics the one in humans and it is possible 
to induce an RA-like arthritis in rodents. This means that we can study genes regulating arthritis 
in mice to then transfer our findings to humans. 
In this study, we set out to identify RA susceptibility genes using mouse models. We bred 
arthritis resistant with arthritis susceptible mice, and then evaluated arthritis susceptibility in 
the offspring. Because the genome of the offspring is a random mosaic of both parental 
genomes, we can deduce which are the genes that affect arthritis susceptibility by testing 
enough mice. Using this approach, we herein identify three genetic regions regulating arthritis 
in mice, and likely also in humans. Our findings contribute to the general understanding of RA 
genetics and we even identify a new potential therapeutic target.  
A summary of our main findings:  
1. In the first study, we find that natural genetic variability enhancing the availability of 
the vitamin D receptor regulates arthritis. Blood vitamin D levels have long been 
speculated to influence susceptibility to several autoimmune diseases in humans and 
our findings support the idea that vitamin D is an important regulator of the immune 
system.  
2. In the second study, we identify the gene SH3GL1 as a novel regulator of autoimmune 
arthritis. The SH3GL1 gene serves as the template for the Endophilin A2 protein, which 
regulates vesicle formation in neural cells. For the first time, we show that this function 
is also highly relevant to immune cells.  
3. In the third study, we find that a genetic region that is important for estrogen-mediated 
regulation of the T cell marker CD2 regulates arthritis specifically in female mice. 
These findings could help explain why women are more susceptible to autoimmune 






Rheumatoid arthritis (RA) affects 0.5-1% of the population and is an important health and 
socioeconomic problem. RA has a high degree of heritability. Thus, extensive efforts have been 
made to better understand the genetic variability contributing to disease susceptibility. 
However, dissecting the genetic component of RA in humans has been difficult due to 
heterogeneity in the human population, multiple testing issues, and lack of accessibility to 
relevant tissues for proof-of-concept studies. Genetic studies in mouse model systems 
circumvent these problems, enhancing the possibility to identify disease regulating genetic 
variants. Here, we use a forward genetics approach in mice to identify and characterize genetic 
determinants of RA and related autoimmune diseases. First, we have mapped quantitative trait 
loci (QTL) regulating experimental arthritis using linkage analysis, and then isolated these QTL 
in congenic strains for in depth functional characterization. Using this approach, we make 
several important observations. 
In the first study, we find that promoter polymorphisms regulating expression of the vitamin D 
receptor affect T cell activation and T cell-driven collagen-induced arthritis. These findings are 
particularly interesting considering the long-standing association between serum vitamin D and 
several autoimmune diseases.  
In the second study, we discover a spontaneous insertion of a long terminal repeat which leads 
to a deficiency in the SH3GL1 gene (Endophilin A2), protecting mice in several arthritis 
models. We are first to identify the immunomodulatory properties of SH3GL1, which may 
prove to be a valuable therapeutic target.  
In the third study, we identify a polymorphic estrogen receptor binding site that regulates 
susceptibility to experimental arthritis and other autoimmune models by interfering with 
estrogen regulation of the T cell marker CD2. These results suggest an important role for CD2 
and estrogen in shaping the sexually dimorphic immune response. Collectively, our findings 
make a significant contribution towards the understanding of RA genetics while demonstrating 
the value of animal models.  
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The human is in constant contact with commensal and pathogenic microorganisms. The 
immune system is an intricate network of specialised cells and mechanisms that provides 
protection from possible infections. The immune system can be broadly subclassified in two 
groups, innate and adaptive.  
The innate immune system is the first line of defence, comprised by a series of non-specific 
mechanism that include skin and mucosal barriers, complement proteins, as well as phagocytic 
and antigen presenting cells (APCs). Innate cells use a series of somewhat unspecific receptors 
to detect, and react to, shared microbial structures such as lipopolysaccharides, proteoglycans, 
unmethylated CpG dinucleotides, or double stranded RNA (1). Activated APCs can recruit and 
expand adaptive effector T cells to generate highly specific immune responses (2).  
Adaptive T and B cells somatically rearrange their receptors during development. In this way, 
millions of T and B cell clones with unique receptor combinations are generated. To be 
activated, T cells require cognate antigen to be presented by APCs. B cells can be stimulated 
by antigen alone or in a T cell-dependent manner to produce antibodies. B cells activated in a 
T cell-dependent manner, however, undergo somatic hypermutation of the B cell receptor 
variable region, resulting in the generation of mature, highly specific antibodies. This process 
results in a flexible and tailored cellular and humoral immune response, but it comes at a cost. 
The same process can generate self-reactive clones that attack our own tissue, causing systemic 
or organ-specific inflammation and destruction, an autoimmune disease.   
Mechanisms are in place to minimize the occurrence of autoreactive events, first at a central, 
then at a peripheral level. Developing bone marrow B cells and thymic T cells with autoreactive 
potential are deleted, receptor edited, or imparted with anergic or anti-inflammatory properties 
during selection (3) (4). Autoreactive cells that escape elimination face obstacles in the 
periphery, such as restricted tissue access and low abundance of antigen. Further, autoreactive 
B cells lacking essential T cell co-stimulation become anergic (5), and improperly 
(co)stimulated autoreactive T cells become apoptotic, anergic or develop regulatory properties 
(6).  
However, these protective mechanisms are not perfect, and tolerance can be breached under 
certain circumstances. Events proposed to break tolerance include exposure of antigen from 
immune privileged sites after injuries (7) (8), cross reactivities between exogeneous and 
endogenous antigens (9), and reactivity to peripherally modified antigens (neoantigens) (10). 
Genetic factors are also critical. For example, rare mutations in single genes affecting central 
or peripheral tolerance such as FOXP3 (11) or AIRE (12) can result in autoimmune conditions. 
Most often, however, genetic susceptibility is determined by multiple common genetic variants 
of low effect sizes with poorly understood and complex underlying mechanisms. Likely, it is 
complex interactions between predisposing genetics and environmental factors that determine 
the susceptibility to autoimmune diseases.  
Today, autoimmune diseases can be treated with different degrees of success but cannot be 
cured. These diseases reduce quality of life in affected persons and are a major socioeconomic 
problem (13). It is imperative that we improve our knowledge to successfully establish new 
therapies and preventive measures. One of the most frequent autoimmune diseases, and the 
focus of this work, is rheumatoid arthritis.   
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2 LITERATURE REVIEW 
2.1 RHEUMATOID ARTHRITIS 
Rheumatoid arthritis (RA) is a multifactorial and chronic autoimmune disease of the joints  
affecting 0,5-1% of the population (14). Like many autoimmune diseases, RA is predominant 
in females, with a female to male ratio of approximately 3:1 (15). RA patients exhibit 
characteristic signs of chronic inflammation in the joints, as evidenced by synovial hyperplasia 
and increased signs of angiogenesis (16) (17) (18). Chronic joint inflammation promotes 
osteoclast formation and leads to increased bone resorption and erosion. If the inflammation is 
not treated, progressive destruction of the joints eventually leads to disability.  
RA can be treated with varying degree of success. 
Therapies focus on stopping inflammation and 
managing pain. Common therapeutic approaches 
include the use of so-called disease modifying 
antirheumatic drugs (methotrexate, 
hydroxychloroquine) in combination with non-
steroidal anti-inflammatory drugs (diclofenac, 
ibuprofen) or glucocorticoids, as well as more 
recently the use fast-acting biologics such as B 
cell-depleting anti-CD20 or TNF blockers. 
RA is diagnosed based on clinical manifestations 
and the characteristic presence of autoantibodies. 
Patients are screened for the presence of  
rheumatoid factors (RF) (19) and anti-
citrullinated protein antibodies (ACPA) (20). RF 
are polyclonal and germline encoded IgM anti-
IgG antibodies that often occur in the context of 
inflammation. ACPAs, on the other hand, are 
promiscuous antibodies capable of binding 
diverse citrullinated autoantigens (21) that are 
highly specific to RA (specificity up to 98%) 
(22).  
ACPAs are not only the gold-standard for RA 
diagnosis but also an important stratification 
criterium, as not all patients have these antibodies 
(sensitivity up to 77%). ACPA positive and 
negative patients differ in e.g. disease progression (23) and genetic risk profiles (24), 
suggesting that RA has different underlying aetiologies. It is unclear how or whether ACPAs 
or RFs are disease modifiers and, in fact, ACPAs precede onset of symptoms (25). It is likely 
that autoimmunity develops in a yearlong subclinical phase before culminating in a chronic 
and destructive disease (21). Our current understanding of RA is limited in that it is derived 
mostly from established disease. 
Figure 1: Illustration of typical joint 
inflammation in patients with 
rheumatoid arthritis. Interphalangeal, 
metacarpophalangeal and wrist joints 
are most often affected. More chronic 
RA may also involve thickening of 
metacarpophalangeal joints and ulnar 




2.2 PATHOPHYSIOLOGY OF ESTABLISHED RA 
Joint inflammation in RA is characterized by the presence leukocyte infiltrates to the joint. 
Local inflammation is perpetuated by the presence of effector cytokines such as IL-1, IL-6, and 
TNFα (26), which are secreted by, and act on, infiltrating and resident cells alike. Both adaptive 
and innate immune cells partake in synovial inflammation (27).  
Cells of the adaptive immune system have generated particular interest given the 
characteristic presence of B cell-derived autoreactive ACPAs and the genetic risk profile in RA 
patients. Many of the genes associated to RA are key players in T cell and B cell activation 
(28), together suggesting an underlying adaptive autoimmune response. Indeed, T cell- and B 
cell infiltration of the joints is characteristic for RA (29), with both these cell types forming a 
large fraction of the synovial infiltrate (30). Infiltrating B and T cells can be found diffusely or 
in lymphocytic aggregates (31, 32). Here, they seem to interact productively as ACPAs evolve 
over time (33), suggesting a T cell-dependent B cell activation. The relevance of both of these 
cell types for pathogenesis is further substantiated by the clinical efficacy of T cell inhibiting 
CTLA4Ig (34), and B cell depleting anti-CD20 (35). Interestingly, anti-CD20 treatment does 
not effectively deplete antibody producing plasma cells (36), highlighting the importance of 
antibody-independent B cell functions. It is known that activated B cells are capable of 
secreting proinflammatory cytokines (37) and potently presenting antigen (38), thus supporting 
activation of synovial (autoreactive) T cells (39) and other cells. This help in activation seems 
reciprocal, as RA T cells also support B cell activation (40).  
Synovial T cells in RA display a contracted T cell receptor (TCR) repertoire characterized by 
patient-individual clonal expansion (41), some of these clones likely recognizing citrullinated 
autoantigens (42). Expanded synovial T cells take on a terminally differentiated and activated 
phenotype (40) (43), losing expression of costimulatory molecules such as CD28, while at the 
same type gaining other receptors that permit activation in an antigen-independent manner (44). 
T cells from RA synovia show increased signs of replicative stress (45)  and are, to some extent, 
resistant to apoptosis (46). These cells potently produce IFN-ƴ, and to some extent IL-17 (47–
50), enhancing inflammation (51) and joint destruction, for example by promoting 
osteoclastogenesis (52). In fact, the frequency of Th1 type cells (producers of IFN-ƴ) correlate 
with disease activity (53). Further insight can be extracted from animal models of RA, which 
demonstrate that transfer of arthritogenic T cells is enough to elicit the development of 
autoimmune arthritis in naïve recipients (54). Thus, although details are still to be sorted out, 
current evidence strongly suggests that T cells are important drivers of the autoimmune 
response in RA. Therefore, the study of T cell modifiers remains central to understanding RA 
pathogenesis.  
Perhaps as a consequence to an initially T cell driven autoimmune response, innate type cells 
are recruited to the joint. Resident and infiltrating innate immune cells are activated by local 
accumulation of proinflammatory cytokines and immune complexes, producing cytokines, 
chemokines, prostaglandins, and leukotrienes in response. Activated neutrophils furthermore 
have the capacity to produce high levels of reactive oxygen species and secrete nuclear 
extracellular traps to promote inflammation (55). Macrophages are present in increased 
numbers in the RA synovial membrane and are believed to contribute to inflammation by 
presenting antigen and producing cytokines such as TNFα, IL6, IL-1β, IL-12 and IL-23 (56). 
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This recruits monocytes and neutrophils, and has repercussions for osteoclast formation, and T 
cell and fibroblast activation. However, recent studies also suggest that resident synovial 
membrane macrophages originally serve to shield and protect articular structures from 
infiltrating cells (57). Mast cells are also expanded in the arthritic synovial membrane, where 
they secrete proteinases (58) and inflammatory mediators (59). Interestingly, they can promote 
T cell responses by presenting antigen (60) but are also capable IL-17 producers themselves 
(61). 
Joint inflammation is not only driven by immune cells, but also by resident cells of 
mesenchymal origin. Activated synovial lining fibroblasts are imprinted with an aggressive 
phenotype that perseveres for several months of culture, producing proinflammatory cytokines, 
chemokines, prostaglandins and matrix-degrading enzymes (62). Similarly, chondrocytes are 
activated by IL-1 and TNFα to secrete proteolytic enzymes, leading to extracellular matrix 
degradation (63).  
Evidently, the rheumatic joint consists of a highly complicated network of proinflammatory 
mediators. A recurring theme is the response to -and secretion of- proinflammatory cytokines, 
in particular IL-1, IL-6, and TNFα. All these cytokines can be readily detected in RA synovia. 
Accordingly, targeting of these pathways presents one of the best therapeutic options in RA 
alongside anti-CD20. While current therapeutic approaches successfully manage synovitis, an 
estimated 5-20% of patients do not respond well to available treatments (64). Additionally, 
biologics carry important added risks such increased susceptibility to infections or 
malignancies (65). To develop new targeted therapies, it is paramount to understand which 
factors predispose an individual to develop RA. 
2.3 PREDISPOSING FACTORS IN RA 
Studies have estimated RA heritability at around 50 % (66). The number is not precise, as 
estimates vary between 12-68%, but it is clear that RA has a significant genetic component. On 
the other hand, this also means that there must be a significant environmental contribution to 
RA susceptibility. We will first briefly cover commonly suggested environmental factors to 
then dedicate more time to RA genetics.  
2.3.1 Predisposing environmental factors 
Several environmental factors have been associated to RA. Some of the most frequently 
mentioned examples include cigarette smoking (67), infections (68) (69), vitamin D status (70), 
use of oral contraceptives (71), and exposure to mineral oils (72).  
It has been suggested that infections may trigger cross-reactivities to self through molecular 
mimicry. For example, Epstein-Barr (69) viral proteins exhibit similarity to HLA-DR4 (73) 
(74) (75). Similarly, smoking (67) and infection with Porphyromonas gingivalis (68), are 
suspected to elicit autoimmune responses by promoting the formation of neo-antigens. Special 
attention has been given to neo-antigen formation as a result of hypercitrullination, given a 
predisposition of RA-associated HLA alleles to bind citrullinated proteins (76), and the 
association between polymorphisms of the citrullinating enzyme PADI4 (77) and RA. Both 
smoking (78) (79) and periodontitis (80) are suspected to promote citrullination, and fittingly 
associate with ACPA seropositive RA (81).  
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A particularly interesting association in the context of study I is that of RA and vitamin D 
status. Several studies have reported an association between low serum vitamin D and 
incidence of RA (82) (83) (84). In study I we demonstrate that the genetic predisposition to 
over and under express the vitamin D receptor affects the immune response in experimental 
models of autoimmunity.  
Similarly, in study III we provide evidence that may help understand associations such as the 
one between RA and use of oral contraceptives (85) (86). A key role for sex hormones in RA 
susceptibility has long been suspected, and this notion is further supported by the female 
preponderance in RA (87), as well as studies reporting disease modifying effects of hormone 
replacement therapy (88) (89). In study III we describe how sex hormones such as estrogen 
may directly contribute to the development of RA by regulating the expression of the T cell 
costimulatory molecule CD2.  
While our studies provide some insight into possible mechanisms fuelling some of the 
environmental associations identified to date, in general, associative studies investigating 
environmental factors in RA have had limited success. Environmental factors may act years 
before RA onset and are thus difficult to identify. Perhaps because of this, studies investigating 
environmental factors are scarce and often lack reproducibility (90). In contrast, more energy 
has been spent understanding the genetic determinants of RA.  
2.3.2 Predisposing genetic factors 
The estimated degree of heritability in RA varies depending on the method used. Comparison 
of disease discordance between monozygotic and dizygotic twins found heritability estimates 
of 12-60%, familial aggregation studies of 50%, and methods considering the cumulative 
influence of all SNPs on RA phenotypic variance suggest a heritability of 19-52% (66). While 
the heritability estimate may not be exact, it is clear that the contribution of genetics to RA is 
significant.  
Already in the late 1970s it was observed that PBMCs from RA patients are unusually 
compatible with each other in mixed lymphocyte cultures (91), and it was quickly recognized 
that this was due to similarities in the HLA alleles of RA patients (92). This association was 
soon refined to the HLA-DRB1 gene and remains the strongest genetic association to RA to 
date (93), accounting for around 30% of the total estimated heritability (94). It has been 
proposed that several of the HLA-DRB1 susceptibility alleles share a common amino acid 
sequence in the third hypervariable region of DRβ1 (shared epitope hypothesis (92)). This 
shared motif may favour binding of arthritogenic peptides although a main candidate remains 
to be singled out.   
The emergence of high throughput sequencing and genotyping methods has enabled genome 
wide association studies that helped clarify the genetic landscape of RA by further identifying 
hundreds of non-MHC risk loci. Interestingly, many of the non-MHC associations are to genes 
relevant to T cell biology and activation, further cementing the importance of T cells for RA 
pathology. Some of the most cited findings include PTPN22, STAT4, TRAF1-C5, IL2RA, 
CD28, and CTLA4 (95), as well as more recently Th17-related CD26 and CCR6 (96) among 
others. T cell-unrelated genes with other relevant functions, such as the citrullinating enzyme 
PADI4 (95), have also been detected. Some of these associations can be ethnic group-specific, 
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such as is the case for HLA-DRB1 alleles or for Caucasian-specific PTPN22, but most 
reproducible associations are shared across populations (97). In contrast, seropositive and 
seronegative RA seem to have a different genetic risk factors (24). For example, HLA-DRB1 
and PTPN22 seem to associate primarily with seropositive RA (98) (99).  
Despite the considerable progress made by modern genetic association studies, it should be 
noted that the newfound loci only make small individual contributions to explaining the overall 
heritability of RA (figure 2). Cumulatively, the current genetic findings explain an estimated 
20% of the total phenotypic variance (97) as opposed to approximately 40% estimated by 
familial and twin studies. This gap has been appropriately termed missing heritability and 
remains an important gap in the genetic understanding of RA.  
 
Figure 2. Cumulative proportion of the total phenotypic variance explained by findings of 
current genome wide association studies. Adapted from Viatte and Barton, 2017 (66). CC-BY 
4.0. 
2.3.3 Limitations of human genetic studies 
The missing heritability can be explained by an over-estimation of the heritability in twin 
studies due to limited sample numbers, but also by failure of modern genome wide association 
studies to capture all genetic variation due to technical limitations. For example, genome wide 
scans are designed to detect common variants and are blind to low-frequency variants (100). 
This is problematic because RA likely cannot be explained only through common genetic 
variation (101). Further, key but structurally complex genetic regions can be excluded from 
analysis due to technical difficulties (102). It should also be considered that genotyping markers 
may be in incomplete linkage disequilibrium with causative variants (103). Also problematic 
is the analysis of higher order interactions to be able to account for the likely very relevant 
contribution of gene-gene (epistasis) and gene-environment interactions. Work from model 
organisms such a Drosophila melanogaster has made clear that complex traits are shaped by 
many genetic variants of moderate effect size that act in concert with each other and with the 
environment (104).  
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Last but not least, human genetic association studies also suffer from statistical limitations. 
They lack sensitivity towards loci of weak effect size (105) given the heterogeneity in the 
human population and high statistical thresholds imposed by multiple testing issues (106) 
(107). As a result, it is likely that several risk loci remain to be identified. Figure 3 visualizes 
the astounding differences in power when trying to detect strong versus moderate-to-weak RA 
susceptibility loci. This is unfortunate, as we demonstrate in the present work that 
polymorphisms in genes with moderate effect size are likely critical co-determinants of disease 
development and perpetuation. We find that polymorphisms in genes such as VDR, CD2, or 
SH3GL1 can be critical to fine-tuning T cell responses and inflammation.  
 
Figure 3: Regional association plots showing strength of association with RA across the HLA-
DRB1, PTPN22, and CD2 locus. Black bars give an approximation of the respective gene. The 
genome-wide significance threshold is indicated by the lower black line. GWAS summary 
statistics were extracted from the IEU open GWAS project (108).  
Once a candidate risk locus is identified, further resistance comes in the form of functional 
interpretation. Unfortunately, most identified variants in genetic association studies concentrate 
in non-coding regions (109) (probably of regulatory nature (110)) and are thus difficult to 
interpret. Often, non-coding variants have regulatory properties, affecting regulation of nearby 
genes (111) (112). However, clarifying these mechanisms is time and resource consuming, a 
process further impeded by cell type or general context specificity of the effects of some 
variants (113). Additional difficulty is given by the fact that a sequenced SNP can be in high 
linkage disequilibrium to actual causative variants. 
Evidently, disentangling the genetic component of RA is complicated. Complementary 
approaches to human genetic association studies are needed to broaden our understanding of 
genetic variants contributing to disease susceptibility. Using animal models of arthritis, we 
demonstrate in study I and study III how non-coding variants can control gene expression to 
regulate immune phenotypes.  
2.4 USING MOUSE MODELS TO STUDY RA GENETICS  
Contrary to human samples, work with animal models provides stable experimental conditions, 
genetic uniformity, accessibility to disease-relevant tissues, and a broad genetic toolkit for 
functional characterization of candidate genes.  
Mice and human shared a common ancestor 60-80 million years ago, but identity and 
arrangement of genes have largely stayed the same (114). The mouse and human genome are 
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highly conserved (115). This is also true for immune biology, although it should be recognized 
that discrete differences exist between species (116) (117) (118). Thus, rodents are an excellent 
model system to identify and characterize genetic factors regulating immune, as well as other,  
traits. In theory, it is possible to dissect the genetic component of a complex trait using only a 
few hundred mice (119), whereas in humans the same effort may require tens of thousands of 
individuals (120). Optimally, of course, human and mouse studies can be integrated, with 
findings from each species informing the biology of the other. To generate relevant and 
translatable findings, mouse genetic studies require well characterised model systems closely 
resembling the human trait or pathological condition under study.  
2.4.1 Inducing RA-like arthritis in mice 
Several models exist to induce RA-like autoimmune arthritis in mice and rats. Many of these 
models consist in immunizing mice with common cartilage proteins in adjuvant. Some 
examples include collagen type II (121) and type XI (122), as well as cartilage oligomeric 
matrix protein (123). Nevertheless, it is also possible to induce arthritis using systemically 
expressed antigens such as glucose-6-phosphate isomerase (124) or using mineral oils, such as 
is the case in pristane-induced arthritis (125). This last model is particularly interesting 
considering the association between RA and exposure to mineral oils (72). Not all arthritis 
models need to be induced. Mice with transgenic overexpression of TNF-α (126) or mice with 
a spontaneous mutation in the T cell signalling ZAP-70 protein (127) develop spontaneous 
arthritis. 
In the present work, we have mostly employed the collagen-induced arthritis (CIA) model 
(121), as it is a well characterized and widely used rodent model of RA with several parallels 
to the human autoimmune condition. In this model, an autoimmune arthritis is triggered by 
immunizing mice with heterologous bovine collagen type II (bCII) in Complete Freund’s 
Adjuvant (128). This elicits an autoimmune response driven by CII autoreactive T cells (129) 
(130) (131) and characterized by the development of arthritogenic autoantibodies (132). A 
typical CIA experiment is depicted in figure 4. Much like in RA, CIA mice exhibit progressive 
and severe joint lesions with T cell infiltrates (133), cartilage injury, bone remodelling (134), 
and synovial hyperplasia (135). Similarly, several key RA cytokines are also involved in CIA 
immune pathology, including IL-17 (136), IFN-ƴ (137) , IL-6 (138), TNFα (139), or IL-1β 
(140).  
CIA is a convenient screening model, as it is well characterized, incidence is high in susceptible 
strains, and arthritis development can be easily monitored by scoring visible inflammation of 
front and hind paws. Using this model, our research group has set out to identify genetic 
determinants of autoimmune arthritis in a forward genetics-based approach. ‘Forward’ in this 
case describes the direction of the workflow, starting from a phenotype and working towards 
the unknown underlying genetic mechanism. Importantly, this method is hypothesis-free.  
2.4.2 Mapping quantitative trait loci in the mouse  
The positional identification of risk genes consists of two phases. First, genetic loci affecting a 
quantitative phenotype of interest (quantitative trait loci, QTL) are roughly mapped by linkage 
analysis, or in genetic association studies. Then, the identified QTL are isolated in congenic 
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strains to enable functional studies with the aim of identifying the underlying genetic 
mechanisms. This process is illustrated in figure 5.  
 
Figure 4: Collagen-induced arthritis. A) Typical CIA diseases course in C57BL/10.H2R mice. 
Data summarized as mean (SEM) from n = 15 mice. B) Representative H&E stain of tibia and 
talus in healthy (left) and CIA mice (right). Note increased inflammatory cell infiltrates (violet 
cell nuclei), thickening of synovial layers, and bone erosion in CIA mice. Final magnification 
25 X. C) ELISA showing development of anti-bCII IgG2b antibodies in CIA mice from (A) (day 
35). D) Flow cytometry plots showing IL-17 and IFN-γ production in CD4+ lymph node T cells 
from CIA mice after in vitro recall with bCII. The dot plot on the left (blue) is from an 
immunized mouse that did not develop arthritis, and the one on the right (red) from a mouse 
that developed visible arthritis. bCII, bovine collagen type II. 
Congenic strains are created by intercrossing a donor with a recipient strain, and then 
backcrossing the offspring to the recipient strain over several generations while selecting for 
the genetic locus of interest. Once done, a congenic mouse has the donor allele on a single, 
selected genomic locus on an otherwise recipient background. In this way, an arthritis 
susceptibility locus can be isolated on an arthritis resistant background or vice versa. 
Established congenic mouse strains allow detailed study of a QTLs in a genetically controlled 
environment. Such strains have for example been used in pioneering work to demonstrate the 
importance of the major histocompatibility H-2 locus in the development of adaptive immune 
responses (141). 
Much like in human genetic studies, the study of QTL in animals is not straightforward. QTL 
identified from F2 crosses are usually large, often containing tens to hundreds of polymorphic 
genes that differ between parental recipient and donor strains. In its simplest form, QTL 
resolution can be increased by further backcrossing to parental strains or further (advanced) 
intercrossing of F2 mice (142, 143). The interval of interest can be isolated in interval-specific 
congenic strains that are further intercrossed. Recombinants within the interval of interest are 
then selected and phenotyped. This procedure is time and resource consuming but can result in 
small 1-2 Mbp long fragments that contain 10-20 polymorphic genes. To make achieving single 





Figure 5. Positional identification of genes regulating complex traits using mouse models. 
A suitable mouse model is selected to approximate human disease, in this case CIA. For linkage 
analysis, arthritis susceptible (donor) and resistant (recipient) strains are crossed, and the 
resulting F2 mice are individually genotyped and phenotypically evaluated. Using 
computational analysis, one can establish which genetic markers segregate with the phenotype 
of interest. The logarithm of odds (LOD) score estimates the concordance between a genetic 
marker and a phenotype. F2 mice of interest are then backcrossed to a parental strain to 
generate congenic lines. Repeated backcrossing progressively reduces the overall genetic 
contamination, halving the genetic content of the donor each generation. After 10 rounds of 
backcrossing, the congenic strain differs only at a defined genetic locus from the recipient 
parental strain. This locus can be further refined by backcrossing or intercrossing (144). The 
resulting congenic mice are used for further genetic and functional analysis.  
One such example are recombinant inbred lines (RIL). Here, F2 mice are randomly intercrossed 
over several generations to accumulate recombinations, and the resulting mice then sibling 
mated for enough generations to generate identical offspring. Importantly, the resulting 
commercially available lines need only be characterised once on a genotypic level and can then 
be screened for several phenotypes of interest. The collaborative cross project (145) builds on 
the idea of RIL but uses 8 (instead of the conventional 2) founder strains carefully selected to 
maximize genetic diversity. The use of CC mice could potentially result in QTL resolution of 
approximately 8 Mbp (146). This resolution can however be further improved by the use of 
complementary methods such as yin-yang crosses (147). The limiting factor in the use of RI 
mice is the amount of mice required to resolve phenotypes and the attached cost and logistics 
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of maintaining thousands of lines. Furthermore, RIL often are bad breeders due to extensive 
inbreeding.  
Breeding problems can be circumvented by using outbred heterogeneous stock (HS) mice 
(148)(149). HS mice result from advanced intercross of several inbred lines bred in pseudo-
random manner to minimize loss of genetic variability. Recombinations accumulate over 
generations so that it becomes technically feasible to map QTL with sub-Mbp accuracy.  Every 
mouse is unique and must be individually genotyped in a genome wide scan much like in 
human studies. The disadvantages of genome-wide analysis using HS mice lies in the 
complexities of the analysis, need for large cohorts (thousands of mice), high-density 
genotyping required (>6000 markers), possibility of false positives, and multiple testing issues. 
Finally, it is possible to avoid breeding work altogether by mapping QTL in silico. Since 
common inbred mouse strains have shared ancestry, it is possible to identify regions identical 
by descent affecting quantitative traits. Here, statistical power can be low, as there is only a 
limited number of inbred lines available, and assumptions need to be made regarding 
conservation and inheritance pattern of identified haplotype blocks between inbred strains and 
original founders. Further, a general limitation from genetic associations studies are false 
positives (150). Regardless of the method used for mapping QTL, ultimately linkage analysis 
and further functional studies are needed to conclusively prove findings from association 
studies. 
2.4.3 Arriving from QTL to causative gene 
Distilling a causative genetic variant from a QTL is a challenging endeavour (151) (152). 
Usually, the driving genes or variants in a QTL cannot be exactly positioned but instead need 
to be inferred. For example, polymorphic genes within a QTL may be prioritized if they are 
immediately relevant to the investigated trait, especially in the presence of non-synonymous 
polymorphisms (153) (154) (155). Likewise of interest, may be polymorphic genes exhibiting 
altered expression levels (156), for example as a consequence of non-coding polymorphisms 
in promoters or enhancers. Once a candidate gene is singled out, the hypothesis is tested by 
complementary approaches, to demonstrate functional relevance of the proposed candidate.  
Popular strategies to demonstrate functional relevance include knockout, inhibition, or 
overexpression of the candidate transcript in a relevant setting (157), as well as stimulation or 
inhibition of the target protein using agonists or antagonists, respectively. A particularly elegant 
method is quantitative complementation, where congenic mice are crossed to a null allele of 
the candidate gene to compare the ability of the congenic and wildtype alleles to compensate 
for the deficiency of the gene under investigation (158). Finally, the identified pathway should 
also be explored in humans to corroborate overall relevance of the findings obtained in mice.  
While systematic mutagenesis or systematic knockout may seem like more straightforward 
alternatives to genetic mapping studies, these approaches have their own limitations (159). An 
approximated 15% of genes are essential and are thus not optimal target for knockout strategies. 
Further, knockouts approaches result in complete loss of gene function, which does not reflect 
the physiological differences generated by natural variation. As a result, knockouts may elicit 
compensatory mechanisms or disrupt important genetic or protein interactions, resulting in 
artificial phenotypes that may not mirror the effects of common genetic variation. Therefore, 
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established congenic strains and linkage analysis remain a valuable tool as they not only allow 
the conclusive identification of important genetic determinants, but also provide a 





3 RESEARCH AIMS 
The genetic component of complex autoimmune diseases such as RA remains poorly 
understood. To aid in this process, we previously set out to identify QTLs critical to the 
development of autoimmune arthritis in mouse and rat model systems. The aim of this study 
was to identify and characterize the genetic polymorphisms and molecular pathways 
underlying several previously reported QTL.  
Specifically, the aims were as follows: 
• Identify the genetic and molecular mechanisms driving Cia37 (142) 
• Identify the genetic and molecular mechanisms driving Cia21 (160) 





4.1 A brief overview of the animal models applied in this study 
 
Collagen-induced arthritis. CIA is induced by immunizing mice intradermally with 
heterologous collagen type II in CFA. Susceptible mice develop joint inflammation 
characterised by synovitis, pannus formation, and cartilage and bone damage. CIA is MHC,  T 
cell, and B cell dependent. This model is described in more detail under 2.4.1. 
Pristane-induced arthritis. Rats immunized with a single intradermal pristane injection 
develop severe and chronic arthritis with symmetrical joint inflammation. PIA is MHC and T 
cell dependent and indeed T cells infiltrates can be found in PIA joints. However, the exact 
mechanism remains unclear as possible immunodominant T cell or B cell epitopes are not 
known. In contrast to CIA, B cells are considered less important in PIA because serum does 
not transfer disease (162). 
Glucose-6-phosphate isomerase-induced arthritis. Transgenic K/BxN mice develop 
antibodies against the GPI protein, causing spontaneous arthritis. GIA can also be induced by 
immunizing mice with GPI full protein or immunodominant peptide hGPI325-339. Mice 
develop a monophasic arthritis that is T cell and B cell dependent (163). Anti-GPI 
autoantibodies can be found in a subset of RA patients (164).  
Collagen antibody-induced arthritis. Arthritis is induced through intraperitoneal 
injection of a cocktail of monoclonal arthritogenic antibodies targeting different epitope of the 
collagen type II protein. Mice develop a short lived monophasic arthritis that is mediated by 
neutrophils and macrophages activated by the presence of antibody aggregates on the cartilage. 
In this context, complement and FcγRs seem to play important roles. CAIA is T and B cell 
independent, and a useful model to study the effector phase of CIA (165). 
Delayed-type hypersensitivity. The DTH model is, in essence, an in vivo antigen recall 
assay driven by Th1-type cells infiltrating the skin (166). Mice are sensitized by immunizing 
with antigen in CFA, and antigen-specific T cells are allowed to expand for 10 days. Thereafter, 
mice are challenged with antigen intradermally and tissue swelling is measured after 24-72hrs 
using a calliper to evaluate T cell responses to the antigen.   
Experimental autoimmune encephalomyelitis. EAE is a model of multiple sclerosis. 
Mice are immunized intradermally with myelin derived antigen emulsified in CFA. Pertussis 
toxin can be administered to increase susceptibility. Mice can be immunized with myelin 
oligodendrocyte protein, proteolipid protein, myelin basic protein, or spinal cord homogenate. 
The result is a progressive, ascending paralysis of the extremities that begins at the tail. 
Paralysis is caused by monocytes and T cells infiltrating the central nervous system and causing 
axonal demyelination. CD4+ T cells are central for EAE with contributions from Th1 and Th17-
type cells chiefly producing IFN-γ, IL-17, and GM-CSF. Both myelin-reactive CD4+ and CD8+ 
T cells can transfer EAE, and are required to induce it. B cell-derived autoantibodies seem less 
critical, with B cell acting mainly to support T cell responses (167). 
DSS-induced colitis. DSS-induced colitis is a quick, 10 day model of inflammatory 
bowel disease. Administration of dextran sodium sulfate (DSS) in the drinking water induces 
severe colitis in susceptible mice by damaging the intestinal epithelium. Disease activity is 
evaluated by following rectal bleeding, weight loss, and stool consistency. This model is driven 
by innate cells like neutrophils and monocytes, and is T and B cell independent (168). 
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5 RESULTS AND DISCUSSION 
5.1 Study I - Vitamin D receptor polymorphisms regulate T cells and T cell-
dependent inflammatory diseases. 
In this study we positionally identify polymorphisms in the vitamin D receptor (VDR) promoter 
as regulators of T cells in autoimmunity. We find that mice that overexpress VDR in activated 
autoreactive T cells develop more severe autoimmune arthritis and that physiological levels of 
vitamin D are required for normal T cell biology and activation. Due to the physiological nature 
of our model, we can rule out calcaemic confounding factors. We also show that lymphocytes 
in rheumatic joints highly upregulate VDR, suggesting that our finding are relevant to human 
RA. In conclusion, our results suggest an inflammatory role for VDR in activated T cells.  
The immunomodulatory properties of vitamin D were first recognized when it became evident 
that cod liver oil, which is high in vitamin D, arrested development of tuberculosis (169) (170). 
Further studies then showed that vitamin D availability is critical to innate immune responses 
and bacterial clearance. At the same time, however, vitamin D deficiency has been associated 
to several autoimmune conditions (171) (172), and together with in vitro studies fuelled the 
idea that vitamin D may have a key immune dampening -rather than activating- role during 
adaptive responses (173) (174) (175) (176). Naturally, the concept of vitamin D as a dietary 
and inexpensive supplement to help restrain inflammation generated great interest.  
However, whether vitamin D has meaningful immunoregulatory properties in a biological 
context has remained questionable, as the beneficiary effects of vitamin D supplementation in 
double-blinded clinical trials are not entirely convincing (177) (178) (179). Moreover, studies 
often demonstrate immunomodulatory properties of vitamin D using supraphysiological doses 
that provoke undesired calcaemic side effects. Our study brings a unique perspective to this 
issue by exploiting naturally conserved genetic variation to investigate the immunomodulatory 
effects of vitamin D and VDR in a physiological setting. Our findings indicate that VDR in a 
physiological range supports T cell activation, and, in a broader sense, help cement the 
importance of vitamin D for immune system biology. 
5.2 Study II - Endophilin A2 deficiency protects rodents from autoimmune 
arthritis by modulating T cell activation. 
This work originated from the observation that a subset of rats in the otherwise highly arthritis-
susceptible DA strain inexplicably became resistant to arthritis. Using linkage analysis, we 
found this protective phenotype to be driven by a QTL on chromosome 9 (Pia43). Sequence 
analysis revealed a spontaneous insertion of a viral long terminal repeat in the first intron of 
the SH3GL1 gene, resulting in silenced transcription of SH3GL1. We speculated that SH3GL1 
deficiency was protecting rats from arthritis, and indeed could confirm this observation in 
SH3GL1 knockout mice. Functional characterization revealed that SH3GL1 affected T cell 
activation by interfering with TCR internalization. Finally, we showed that SH3GL1 is 
overexpressed in PBMCs from RA patients, suggesting a role for SH3GL1 in the pathogenesis 
of autoimmune arthritis. 
Genetic and immunological studies strongly suggest that aberrant activation of autoreactive T 
cells is key to the chronicity and lack of resolution in autoimmune diseases. Although 
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autoreactive T cells are promising therapeutic targets, development of (antigen-specific) T cell-
based immunotherapies has proven challenging. Monoclonal antibody-based targeting of broad 
T cell populations (180) has had limited success, and more specific strategies are either still 
under development (vaccination-type strategies) (181) or have proven ineffective (oral type II 
collagen) (182) (183). Thus, there is a need to broaden our understanding of T cell regulation 
with the aim of improving T cell-based therapies. Our results contribute to this by identifying 
SH3GL1 as a key regulator of T cells and a promising new therapeutic pathway to target 
(autoreactive) T cells.  
5.3 Study III - Polymorphic estrogen receptor binding site causes CD2-
dependent sex bias in the susceptibility to autoimmune diseases 
In this study we identify a polymorphic estrogen receptor binding site (ERBS) leading to sex-
dependent differences in several models of autoimmunity. This ERBS orchestrated expression 
of surrounding genes in an estrogen-dependent manner, including the T cell costimulatory 
molecule CD2. As a result, polymorphisms in this ERBS interfered with hormone-dependent 
regulation of gene expression. Sex-specific changes in CD2 expression then culminated in 
sexually dimorphic T cell responses. Our findings have several implications for human 
autoimmunity.  
First, we provide functional evidence that polymorphisms in the CD2 locus are relevant to RA 
susceptibility. The CD2 locus has been associated to RA before (184, 185), however 
association data is limited and functional evidence lacking. We demonstrate that 
polymorphisms in the CD2 locus are important modulators of autoreactive T cell responses and 
autoimmune disease in mice. Further, we show that CD2 expression is increase in RA synovia 
and that CD2 expression correlates with disease activity, suggesting that CD2 polymorphisms 
affecting CD2 expression are likely relevant to the development or perpetuation of human 
autoimmunity.  
Secondly, this study gives insight into the mechanisms driving sex differences in the immune 
response. RA not only occurs predominantly in females, but its symptoms often recede during 
pregnancy (186) (187) and have even been coupled to the menstrual cycle (188). Further, oral 
contraceptives (85) (86) and HRT (88) associate positively with RA (although contradictory 
reports exist (189)). Together, these data suggest an important immune modulatory function of 
sex hormones. Indeed, both CD4+ T cell and humoral responses are sex biased (190) and often 
stronger in women. ERs are expressed in CD4+ T cells (191), and likely play important 
regulatory functions during immune responses. This is supported by studies showing that E2 
promotes T cell responses at physiological concentrations (192) (193) (194). In the present 
study, we show that E2 shapes the sexually dimorphic immune response by regulating the 
expression of the T cell activation marker CD2. 
Finally, this study also demonstrates the importance of sex-genotype interactions for regulating 
(auto)immune responses. Sex-genotype interactions are an attractive mechanism of action to 
explain the sexual dimorphism in autoimmunity, but it has been challenging to collect 
conclusive evidence beyond associative findings. Our study not only shows that genotype-sex 
interactions shape (auto)immune phenotypes, but also provides a tangible mechanism by 
demonstrating how polymorphisms can act in a sex-specific manner by interfering with binding 
of key hormone receptors.  
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6 CONCLUDING REMARKS 
There is a clear need to further understand the substantial genetic component in RA and in other 
autoimmune diseases. Technological advances in sequencing and high throughput genotyping 
made the full characterization of complex genetic diseases such as RA a tangible goal. 
However, this has been bottlenecked by unexpected degrees of complexity. While the 
expectation to genetic associations studies was to find a discrete number of moderate effect 
size-QTL with single underlying genes, complex diseases instead turned out to be governed by 
a sea of difficult to interpret and interacting low effect size QTL (<5%) (146) (160) (195), with 
only a few dominant QTL of strong effect size. A reason for this structure may be high selective 
pressure on variants with large effect sizes. 
Cloning QTL with small effect size is fundamentally problematic because it means identifying 
and understanding small and interweaving molecular and genetic effects. The problem of 
understanding complex traits is, at its core, the problem of understanding small genetic effects. 
This is only aggravated by genotype-environment interactions. To successfully study complex 
traits, model systems are required that reduce environmental and genetic variability while 
enabling thorough functional analysis. Mouse models meet these requirements while 
accurately recapitulating human (patho)physiology. Even in mouse models, however, 
achieving single gene resolution from large QTLs is laborious. QTNs and causative genes need 
not only be identified, but also functionally interpreted. Only a few studies using congenic 
strains have been able to achieve this (155) (196). Historically, cloned QTL have had 
exceptional effect sizes. Of over 2000 reported QTL, only 1% have arrived at a single gene 
(146).  
The results we present here are the culmination of more than a decade of successful genetic 
work to identify and characterize key genetic determinants of autoimmune arthritis in mice. 
Our findings aid in our understanding of the genetic architecture of complex autoimmune 
diseases, providing functional evidence for the relevance of non-coding genetic variants in the 
development of complex traits. The importance of our findings is not limited to RA, as complex 
autoimmune diseases share many mechanistic features. This study thus helps clarify recurring 
questions in the field of inflammation and autoimmunity, such as the contribution of vitamin 
D receptor polymorphisms (197) or the importance of sex-genotype interactions for the 
development and perpetuation of autoimmune diseases (198). Additionally, we identify a novel 
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